Robert Kim - Feb 5, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Medical Officer
Signature
By: /s/ Scott Bizily, Attorney-in-Fact for Robert Young Kim
Stock symbol
FDMT
Transactions as of
Feb 5, 2024
Transactions value $
-$370,948
Form type
4
Date filed
2/7/2024, 08:32 PM
Previous filing
Dec 13, 2023
Next filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $224K +12K +752.35% $18.66 13.6K Feb 5, 2024 Direct F1
transaction FDMT Common Stock Sale -$361K -12K -88.27% $30.05 1.6K Feb 5, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $94.7K +6K +376.18% $15.78 7.6K Feb 5, 2024 Direct F1
transaction FDMT Common Stock Sale -$180K -6K -79% $30.05 1.6K Feb 5, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $48.2K +6K +376.18% $8.04 7.6K Feb 5, 2024 Direct F1
transaction FDMT Common Stock Sale -$180K -6K -79% $30.05 1.6K Feb 5, 2024 Direct F1
transaction FDMT Common Stock Sale -$16.6K -552 -34.61% $30.05 1.04K Feb 5, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -12K -8% $0.00 138K Feb 5, 2024 Common Stock 120K $18.66 Direct F2
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -6K -8.57% $0.00 64K Feb 5, 2024 Common Stock 6K $15.78 Direct F3
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -6K -10% $0.00 54K Feb 5, 2024 Common Stock 6K $8.04 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023.
F2 25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F3 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F4 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.